<p><strong>Asthma</strong>: Omalizumab is indicated for patients 6 years of age and older with moderate to severe persistent&nbsp;asthma&nbsp;who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Omalizumab has been shown to decrease the incidence of asthma exacerbations in these patients.<br />
<br />
<strong>Chronic Idiopathic Urticaria (CIU)</strong>: Omalizumab is indicated for the treatment of adults and adolescents 12 years of age and older with chronic&nbsp;idiopathic&nbsp;urticaria&nbsp;who remain symptomatic despite H1 antihistamine treatment.</p>